Aardvark Therapeutics, Inc. Common Stock (AARD) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 4 Buy, 4 Hold.
The consensus price target is $29.33 (low: $6.00, high: $47.00), representing an upside of 477.4% from the current price $5.08.
Analysts estimate Earnings Per Share (EPS) of $-2.86 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.59 vs est $-2.86 (beat +44.3%). 2025: actual $-2.93 vs est $-2.93 (beat +0.1%). Analyst accuracy: 60%.
AARD Stock — 12-Month Price Forecast
$29.33
▲ +477.36% Upside
Average Price Target
Based on 8 Wall Street analysts offering 12-month price targets for Aardvark Therapeutics, Inc. Common Stock, the average price target is $29.33, with a high forecast of $47.00, and a low forecast of $6.00.
The average price target represents a +477.36% change from the last price of $5.08.
Highest Price Target
$47.00
Average Price Target
$29.33
Lowest Price Target
$6.00
AARD Analyst Ratings
Buy
Based on 8 analysts giving stock ratings to Aardvark Therapeutics, Inc. Common Stock in the past 3 months
EPS Estimates — AARD
60%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$1.59
vs Est –$2.86
▲ 79.6% off
2025
Actual –$2.93
vs Est –$2.93
▲ 0.1% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — AARD
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
